{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:19:10Z","timestamp":1775035150672,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.seizure.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T03:06:30Z","timestamp":1739329590000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An audit of people with epilepsy, aged 16\u201355 years, taking valproate in UK primary care in 2023\u20134"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2320-8790","authenticated-orcid":false,"given":"I","family":"Minshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-5589","authenticated-orcid":false,"given":"A","family":"Neligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"s9","key":"10.1016\/j.seizure.2025.02.008_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1016\/j.seizure.2025.02.008_bib0002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.02.008_bib0003","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ng217. 30th January 2025."},{"key":"10.1016\/j.seizure.2025.02.008_bib0004","unstructured":"https:\/\/bnf.nice.org.uk\/drugs\/sodium-valproate\/#side-effects Accessed January 2025."},{"issue":"7581","key":"10.1016\/j.seizure.2025.02.008_bib0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(68)91781-9","article-title":"Anticonvulsant drugs and congenital abnormalities","volume":"2","author":"Meadow","year":"1968","journal-title":"The Lancet"},{"key":"10.1016\/j.seizure.2025.02.008_bib0006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/jmg.32.9.724","article-title":"Fetal valproate syndrome","volume":"32","author":"Clayton-Smith","year":"1995","journal-title":"J Med Genet"},{"key":"10.1016\/j.seizure.2025.02.008_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.seizure.2025.02.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017248","article-title":"Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis","volume":"7","author":"Veroniki","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.seizure.2025.02.008_bib0009","unstructured":"https:\/\/www.gov.uk\/drug-safety-update\/antiepileptic-drugs-in-pregnancy-updated-advice-following-comprehensive-safety-review#valproate-reminder-of-the-known-risks-and-requirements 7th January 2021."},{"issue":"9","key":"10.1016\/j.seizure.2025.02.008_bib0010","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"The EURAP Study Group. Declining malformation rates with changed antiepileptic drug prescribing: an observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.02.008_bib0011","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf-0 31st May 2018."},{"key":"10.1016\/j.seizure.2025.02.008_bib0012","unstructured":"https:\/\/www.gov.uk\/drug-safety-update\/valproate-medicines-epilim-depakote-pregnancy-prevention-programme-materials-online. 24th May 2018."},{"key":"10.1016\/j.seizure.2025.02.008_bib0013","unstructured":"https:\/\/www.gov.uk\/drug-device-alerts\/national-patient-safety-alert-valproate-organisations-to-prepare-for-new-regulatory-measures-for-oversight-of-prescribing-to-new-patients-and-existing-female-patients-natpsa-2023-013-mhra 28th November 2023."},{"issue":"3","key":"10.1016\/j.seizure.2025.02.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101755","article-title":"Impaired bone health as a co-morbidity of epilepsy","volume":"36","author":"Andersen","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.seizure.2025.02.008_bib0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.0b013e31825f0466","article-title":"Falls and fractures in patients chronically treated with antiepileptic drugs","volume":"79","author":"Ahmad","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.seizure.2025.02.008_bib0016","volume":"2","year":"2009"},{"key":"10.1016\/j.seizure.2025.02.008_bib0017","unstructured":"https:\/\/www.gov.uk\/drug-safety-update\/antiepileptics-adverse-effects-on-bone 11th December 2014."},{"key":"10.1016\/j.seizure.2025.02.008_bib0019","series-title":"The NHS Confederation 2003","article-title":"Investing in General Practice","year":"2003"},{"key":"10.1016\/j.seizure.2025.02.008_bib0020","series-title":"The epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care","year":"2004"},{"issue":"2","key":"10.1016\/j.seizure.2025.02.008_bib0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2005.11.009","article-title":"The development of a city-wide epilepsy register","volume":"15","author":"Minshall","year":"2006","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2025.02.008_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S1463423611000351","article-title":"Unmet needs in patients with epilepsy, following audit, educational intervention and theintroduction of the New General Practice Contract","volume":"13","author":"Minshall","year":"2012","journal-title":"Prim Health Care Res Dev"},{"issue":"10","key":"10.1016\/j.seizure.2025.02.008_bib0023","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.seizure.2014.07.015","article-title":"Have the New GP Contract and NICE guidelines improved the clinical care of people with epilepsy?","volume":"23","author":"Minshall","year":"2014","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2025.02.008_bib0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.seizure.2013.06.002","article-title":"Bone protection and anti-epileptic drugs: the effect of audit and computer messaging on supplementation prescribing practices","volume":"22","author":"Minshall","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.02.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108778","article-title":"The impact of a clinical review of people with active epilepsy not under shared care by a GP with Special Interest","volume":"134","author":"Minshall","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.02.008_bib0026","unstructured":"https:\/\/www.socscistatistics.com\/tests\/chisquare Accessed January 2025."},{"issue":"3","key":"10.1016\/j.seizure.2025.02.008_bib0027","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy. A systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2025.02.008_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.02.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108354","article-title":"UK general practice: continuing to fail in the care of people with epilepsy?","volume":"124","author":"Minshall","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.seizure.2025.02.008_bib0030","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1093\/brain\/awae128","article-title":"Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy","volume":"147","author":"Mbizvo","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2025.02.008_bib0031","first-page":"1","article-title":"Paternal exposure to antiseizure medicactions and offspring outcomes; a systemic review","author":"Honybun","year":"2024","journal-title":"J NeurolNeurosurg Psychiatry"},{"issue":"10282","key":"10.1016\/j.seizure.2025.02.008_bib0032","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:20:44Z","timestamp":1775024444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"alternative-id":["S1059131125000391"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.02.008","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An audit of people with epilepsy, aged 16\u201355 years, taking valproate in UK primary care in 2023\u20134","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}